论文部分内容阅读
目的观察吉非替尼一线治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法 21例局部晚期和转移性老年NSCLC一线应用吉非替尼250mg/d直至出现肿瘤进展或不可耐受的毒副反应。结果 21例患者中CR3例(14.3%),PR8例(38.1%),SD3例(14.3%),PD7例(33.3%),客观缓解率52.4%,疾病控制率66.7%,中位无进展生存期(PFS)6个月,中位生存时间(OS)8个月,1年生存率33.3%,2年生存率9.5%。主要毒副反应为皮疹发生率52.4%,腹泻发生率33.3%,恶心呕吐发生率13.3%,转氨酶升高发生率9.5%。结论吉非替尼一线治疗老年晚期非小细胞肺癌有较好的疗效和安全性。
Objective To observe the clinical efficacy and side effects of gefitinib in the treatment of senile advanced non-small cell lung cancer (NSCLC). Methods Twenty-one patients with locally advanced and metastatic senile NSCLC received first-line gefitinib 250 mg daily until tumor progression or intolerable side effects occurred. Results Among the 21 patients, CR3 (14.3%), PR8 (38.1%), SD3 (14.3%) and PD7 (33.3%) had an objective response rate of 52.4% and a disease control rate of 66.7% (PFS) for 6 months. The median survival time (OS) was 8 months. The 1-year survival rate was 33.3% and the 2-year survival rate was 9.5%. The main side effects were rash incidence rate of 52.4%, diarrhea incidence rate of 33.3%, nausea and vomiting rate of 13.3%, elevated transaminase incidence of 9.5%. Conclusion The first-line gefitinib treatment of elderly patients with advanced non-small cell lung cancer has good curative effect and safety.